Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.74 |
| ▸ | CAMK2D | Q13557 | 13/20 | 0.58 |
| ▸ | PRKACA | P17612 | 5/20 | 0.57 |
| ▸ | PRKACG | P22612 | 4/20 | 0.57 |
| ▸ | PRKACB | P22694 | 4/20 | 0.57 |
| ▸ | CDK4 | P11802 | 3/20 | 0.57 |
| ▸ | CCND1 | P24385 | 3/20 | 0.57 |
| ▸ | PRKCB | P05771 | 3/20 | 0.57 |
| ▸ | PRKCA | P17252 | 3/20 | 0.57 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.57 |
| ▸ | CDK2 | P24941 | 2/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.57 |
| ▸ | PIM1 | P11309 | 2/20 | 0.57 |
| ▸ | PRKCH | P24723 | 2/20 | 0.57 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.57 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.57 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.57 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5686043 | 0.83 | SIRT2 (0.62) | GSK3BCAMK2DPRKACAPRKACGPRKACB | |
| SCHEMBL6099473 | 0.81 | GSK3B (0.52) | GSK3BCAMK2DIDH1 | |
| SCHEMBL5946249 | 0.79 | GSK3B (0.71) | GSK3BCAMK2DPRKACAPRKACGPRKACB | |
| SCHEMBL6529456 | 0.78 | GSK3B (0.55) | GSK3BCAMK2DPRKACAPRKACGPRKACB | |
| SCHEMBL30999964 | 0.77 | IDH1 (0.49) | GSK3BIDH1 | |
| Ro-316233 SCHEMBL29373011 | 0.75 | PRKCB (1.00) | GSK3BCAMK2DPRKACAPRKACGPRKACB | |
| Ro-316233 SCHEMBL624896 | 0.75 | PRKCB (1.00) | GSK3BCAMK2DPRKACAPRKACGPRKACB | |
| SCHEMBL13917970 | 0.74 | PRKCB (0.78) | GSK3BCAMK2DPRKACAPRKACGPRKACB | |
| SCHEMBL5229864 | 0.74 | CAMK2D (0.59) | GSK3BCAMK2DPRKACAPRKACGPRKACB | |
| SCHEMBL5946111 | 0.73 | IDH1 (0.74) | GSK3BCAMK2DPRKACAPRKACGPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129250-B2 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2006-10-31 | — | — | US | claimed |
| US-20060252045-A1 | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby | WYETH | 2006-11-09 | — | — | US | disclosed |
| WO-2005028678-A9 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH CORP (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1636388-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | Wyeth (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005014584-A9 | 3-(INDOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES,3-(BENZIMIDAZOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES, AND 3-(INDOLIN-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES; THEIR PREPARATION AND USE AS MODULATORS OF APOPTOSIS | AEGERA THERAPEUTICS INC (CA) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005028678-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005014584-A1 | 3-(INDOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES,3-(BENZIMIDAZOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES, AND 3-(INDOLIN-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES; THEIR PREPARATION AND USE AS MODULATORS OF APOPTOSIS | AEGERA THERAPEUTICS INC. (CA) | 2005-02-17 | — | — | WO | disclosed |
| US-6719520-B2 | FOR INHIBITION OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3); TREATMENT AND PROPHYLAXIS FOR DIABETES, CHRONIC NEURODEGENERATIVE CONDITIONS, MOOD DISORDERS SUCH AS SCHIZOPHRENIA AND MANIC DEPRESSION AND HAIR LOSS AND CANCER | SMITHKLINE BEECHAM CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20040010031-A1 | Novel method and compounds | SMITHKLINE BEECHAM P.L.C. | 2004-01-15 | — | — | US | disclosed |
| EP-1119548-A1 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| US-RE36736-E | Substituted pyrroles | HOFFMAN-LA ROCHE INC. (US) | 2000-06-13 | — | — | US | disclosed |
| WO-2000021927-A2 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
| EP-0328026-B1 | SUBSTITUTED PYRROLES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-04-28 | — | — | EP | disclosed |
| US-5057614-A | Antiinflammatory, immunology, bronchodilator agents, cardiovascular disorders | HOFFMANN-LA ROCHE INC. (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0328026-A1 | Substituted pyrroles | F. HOFFMANN-LA ROCHE AG (CH) | 1989-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010031-A1 | Novel method and compounds | GSK3A, GSK3B, GSKIP | GSK3B 2/4885CAMK2D 1010/4885PRKACA 2150/4885 |
| US-20060252045-A1 | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby | BMP4, BMP2, BMP6 | GSK3B 2078/4885CAMK2D 82/4885PRKACA 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.